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Rationale: Increased airway Na1 absorption mediated by epithelial
Na1 channels (ENaC) is a characteristic abnormality in the patho-
genesis of cystic fibrosis (CF) lung disease. However, inhalation
therapy with the ENaC blocker amiloride did not have therapeutic
benefits in patients with CF with established lung disease.
Objectives: We hypothesized that preventive inhibition of increased
Na1 absorption in a structurally normal lung may be required for
effective therapy of CF lung disease in vivo, and that therapeutic
effects of late amiloride intervention may be impeded by the chronic
disease process.
Methods: To test this hypothesis in vivo, we used the bENaC-over-
expression mouse as a model of CF lung disease and determined
therapeutic effects of preventive versus late amiloride therapy on
survival, airway mucus plugging, chronic bronchitis, and airway
remodeling.
Measurements and Main Results: We show that early intervention, i.e.,
from the first day of life, with the intranasal administration of
amiloride significantly reduced pulmonary mortality, airway mucus
obstruction, epithelial necrosis, goblet cell metaplasia, and airway
inflammation in bENaC-overexpressing mice. In contrast, consistent
with previous human trials in patients with CF, amiloride administra-
tion did not have benefits if treatment was started after the de-
velopment of CF-like lung disease in bENaC-overexpressing mice.
Conclusions: We conclude that preventive inhibition of increased
airway Na1 absorption provides an effective therapy for CF-like lung
disease in vivo. These results suggest that amiloride therapymay bean
effective preventive therapy for patients with CF if initiated early in
life before the onset of lung disease.
Keywords: epithelial Na1 channels; airway surface liquid; cystic
fibrosis; pharmacotherapy; mucus
Cystic fibrosis (CF) lung disease remains one of the most frequent
lethal hereditary diseases, and is caused by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR) gene (1,
2). CFTR encodes a cAMP-dependent Cl2 channel and regulates
the epithelial Na1 channel (ENaC) (3–7). In CF airway epithelia,
CFTR-mediated Cl2 secretion is defective and ENaC-mediated
Na1 absorption is increased (8–11). Evidence from in vitro studies
demonstrated that these ion transport defects in CF airways cause
airway surface liquid (ASL) volume depletion, defective mucus
clearance, and mucus adhesion, suggesting that ASL volume
depletion is a key mechanism in the pathogenesis of CF lung
disease (12–14). Further, a selective increase of airway Na1
absorption by airway-specific overexpression of the b-subunit of
ENaC (encoded by the Scnn1b gene) in mice demonstrated that
accelerated Na1 transport alone is sufficient to produce ASL
volume depletion and the subsequent spectrum of CF-like lung
disease, including airway mucus obstruction, goblet cell meta-
plasia, chronic neutrophilic airway inflammation, impaired clear-
ance of bacterial pathogens, and ultimately mortality (15–18).
Further, recent studies identified additional abnormalities in the
lungs of bENaC-overexpressing mice that have been reported less
frequently in patients with CF, including airway epithelial necrosis,
transient airway eosinophilia, and emphysema (17). Taken to-
gether, these results indicated that increased airway Na1 absorp-
tion plays a critical role in the pathogenesis of CF and suggest
ENaC as a pharmacologic target to improve airway surface hy-
dration for treatment of a disease-initiating step in CF lung disease.
However, in previous clinical trials, inhalation therapy with
the ENaC inhibitor amiloride (19) did not demonstrate significant
therapeutic benefits in patients with CF with established lung
disease (20, 21). Recent studies of antimicrobial agents in CF
suggest that early intervention may be more effective in reducing
bacterial infection than treatment of established infection in CF
lung disease (22, 23). Accordingly, we hypothesized that thera-
peutic effects of aerosolized amiloride were also impeded by
factors related to the chronic disease process and that preventive
inhibition of increased Na1 absorption, started in a structurally
normal neonatal CF lung, may be required to effectively treat CF
lung disease. To test this hypothesis in vivo, we used the bENaC-
overexpressing mouse as a model of CF lung disease (15, 16) and
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compared the effects of preventive amiloride treatment versus
amiloride intervention after the onset of lung disease on survival,
airway mucus obstruction, epithelial necrosis, airway remodeling,
and airway inflammation. Some of the results of this study have
been reported previously in the form of abstracts (24, 25).
METHODS
Experimental Animals
All animal studies were approved by the Regierungspräsidium Karls-
ruhe, Germany. The generation of bENaC-overexpressing mice (line
6608) has been described previously (15). Further details on experimen-
tal animals are provided in the online supplement.
Amiloride Treatment Studies
Amiloride hydrochloride (Sigma-Aldrich, Taufkirchen, Germany) was
dissolved in sterile distilled water (ddH2O). Newborn, 5-day-old, and
4-week-old bENaC-overexpressing mice and wild-type littermates were
treated by intranasal instillation of amiloride (10 mmol/L; 1 ml/g body
weight; three times per day) or equal volumes of vehicle (ddH2O) alone
for a period of 13 to 14 days. Pulmonary deposition studies in newborn
mice indicated that approximately 4% of the amiloride dose delivered by
intranasal instillation was deposited into the lungs (see Figure E1 in the
online supplement). During amiloride treatment, growth and survival
were monitored, and deficits in body mass observed in amiloride-treated
mice were replaced by subcutaneous injections of isotonic saline (NaCl
0.9%) as described in the online supplement.
Twelve hours after the last treatment, bronchoalveolar lavage (BAL)
was performed; lungs were removed for histology, morphometry, and
transcript expression studies; and serum and urine were sampled to
determine renal effects of absorbed amiloride on Na1 and K1 concen-
trations as described in the online supplement. To determine the effect of
amiloride on airway epithelial necrosis, bENaC-overexpressing mice
and wild-type littermates were treated from the first day of life for
a period of 3 days and the lungs were removed for histology 12 hours after
the last treatment. To examine if effects of preventive amiloride therapy
during the neonatal period were sustained in the absence of continuous
ENaC blockade, amiloride withdrawal studies were performed as de-
scribed in the online supplement. Finally, to determine if systemic
application of amiloride or NaCl 0.9% had effects on lung disease,
bENaC-overexpressing mice were treated with subcutaneous injections
of amiloride or NaCl 0.9% alone as described in the online supplement
(Figure E3). Endpoint studies were performed by investigators blinded
to the genotype and the treatment of the mice.
BAL Cell Counts and Cytokine Measurements
BAL was obtained and cell counts were determined as previously
described (15). Macrophage size was determined as described in the
online supplement. IL-13 concentrations were measured in BAL using
ELISA (R&D Systems, Minneapolis, MN) according to manufacturer’s
instructions as previously described (17).
Histology and Airway Morphometry
Lungs were removed through a median sternotomy, fixed, paraffin
embedded, sectioned, and stained with hematoxylin and eosin (H&E)
or Alcian blue periodic acid-Schiff (AB-PAS) as previously described (17).
Lungs were sectioned transversally at the level of the proximal intra-
pulmonary main axial airway near the hilus, and at the distal intra-
pulmonary axial airway as described in the online supplement. Airway
mucus obstruction was assessed stereologically by determining mucus
volume density as previously described (17, 26–28). The volume density
of the airway epithelium was determined as a measure of epithelial
height. Goblet cells were identified by the presence of intracellular AB-
PAS–positive material, degenerative airway epithelial cells were identi-
fied by morphologic criteria, and numeric cell densities were quantitated
by counting epithelial cells per mm of the basement membrane. Further
details on morphometry are provided in the online supplement.
Real-Time RT-PCR
Quantitative RT-PCR for Muc5ac, Gob5, bENaC, and Gapdh was
performed on an Applied Biosystems 7500 Real Time PCR System
using TaqMan universal PCR master mix and inventoried TaqMan gene
expression assays according to the manufacturer’s instructions (Applied
Biosystems, Darmstadt, Germany). Relative fold changes in target gene
expression were calculated from the efficiency of the PCR reaction and
the crossing point deviation between samples from the four treatment
groups, and determined by normalization to expression of the reference
gene Gapdh, as previously described (17).
Statistics
Data were analyzed with SigmaStat version 3.1 (Systat Software,
Erkrath, Germany) and are reported as mean 6 SEM. We performed
statistical analyses using Student’s t test, Mann-Whitney Rank Sum test,
one-way ANOVA, Kruskal-Wallis ANOVA on Ranks, and Kaplan-
Meier survival analysis as appropriate, and P , 0.05 was accepted to
indicate statistical significance.
RESULTS
Preventive Amiloride Therapy Reduces Mortality of CF-like
Lung Disease in bENaC-overexpressing Mice
The lungs of bENaC-overexpressing mice are structurally
normal at birth, but develop central airway mucus obstruction
in the first days of life (15). To evaluate effects of preventive
amiloride therapy on CF-like lung disease, amiloride administra-
tion to bENaC-overexpressing mice was started on the first day
of life (i.e., before the onset of lung disease) using a protocol of
intranasal administration of amiloride (10 mmol/L; 1 ml/g body
weight) or vehicle (ddH2O) alone three times daily for a period of
2 weeks. Wild-type littermates were treated with the same pro-
tocol to assess for pulmonary toxicity of amiloride therapy. Renal
effects of absorbed amiloride were determined by measuring Na1
and K1 concentrations in serum and urine, and weight loss due to
diuresis. Volume losses were replaced by subcutaneous injections
of isotonic saline (NaCl 0.9%) (Figure E1).
Using this treatment protocol, we first measured the effect of
preventive amiloride therapy on survival. Similar to the sponta-
neous pulmonary mortality observed in previous studies (15, 17),
vehicle-treated bENaC-overexpressing mice exhibited a mortal-
ity rate of approximately 50% (Figure 1A). Preventive amiloride
treatment resulted in a delayed onset, with an overall reduction of
pulmonary mortality by approximately 70% in bENaC-over-
expressing mice. Amiloride had no adverse effects on survival in
wild-type littermates (Figure 1A).
Early Amiloride Therapy Prevents Airway Mucus Obstruction,
Goblet Cell Metaplasia, and Mucus Hypersecretion in
bENaC-overexpressing Mice
Our previous studies indicated that mortality in bENaC-over-
expressing mice is caused by asphyxia due to severe postnatal
central airway mucus plugging, and demonstrated that surviving
mice develop mucus obstruction, epithelial remodeling with
goblet cell metaplasia and epithelial thickening, and mucus
hypersecretion in intrapulmonary airways during the first weeks
of life (15, 17). We, therefore, next measured the effects of
preventive amiloride therapy on these characteristic pathologic
features in surviving bENaC-overexpressing mice. As predicted
from previous studies, airway mucus content was significantly
elevated in vehicle-treated bENaC-overexpressing mice versus
wild-type littermates (Figures 1B and 1C) (17). Preventive
amiloride treatment significantly reduced airway mucus obstruc-
tion to near-normal values in proximal and distal airway regions
of bENaC-overexpressing mice (Figures 1B and 1C). Further,
early amiloride therapy prevented goblet cell metaplasia and
epithelial thickening observed in distal airways of vehicle-treated
bENaC-overexpressing mice (Figures 1D and 1E). Inhibition of
goblet cell metaplasia and airway mucus obstruction was paral-
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leled by a significant reduction of transcript levels of the goblet
cell marker Gob5 and the airway mucin Muc5ac in lungs from
amiloride-treated compared with vehicle-treated bENaC-over-
expressing mice (Figures 2A and 2B). In contrast, preventive
ENaC blocker therapy had no effect on expression of bENaC
mRNA in lungs from bENaC-overexpressing mice (Figure 2C),
indicating that therapeutic effects of amiloride were conferred by
pharmacologic inhibition of ENaC-mediated Na1 absorption
rather than reduced bENaC expression.
Evaluation of lungs from vehicle- and amiloride-treated wild-
type mice did not reveal any signs of pulmonary toxicity caused by
amiloride therapy. Specifically, preventive amiloride therapy did
not alter airway mucus content, goblet cell numbers, epithelial
height, or Gob5 and Muc5ac expression in amiloride-treated
compared with vehicle-treated wild-type mice (Figures 1 and 2).
Loss of body mass due to increased diuresis and excretion of
Na1 in the urine of amiloride-treated bENaC-overexpressing
and wild-type mice (Figure E1) indicated that intranasally
administered amiloride was at least partially absorbed, resulting
in systemic effects including ENaC blockade in the kidney. To
examine the possibility that therapeutic benefits of intranasal
amiloride treatment (Figures 1 and 2) were caused by systemic
rather than by topical inhibition of ENaC in the airways, we
performed studies in which bENaC-overexpressing mice and
wild-type littermates were treated systemically with subcutane-
ous injections of amiloride (0.1 mmol/l, dissolved in NaCl 0.9%;
100 ml/g body weight; 3 times per day), or equal volumes of NaCl
0.9% alone, for a period of 2 wk. Of note, the dose of sub-
cutaneously administered amiloride was equivalent to the total
dose used in intranasal treatment studies (Figures 1 and 2).
Systemic amiloride treatment caused more severe growth re-
tardation in mice of both genotypes than topical treatment, but
did not have therapeutic effects on pulmonary mortality, airway
mucus obstruction, or goblet cell metaplasia in bENaC-over-
expressing mice (Figures E3A–E3D). Treatment with subcuta-
neous NaCl 0.9% alone also had no effect on the pulmonary
phenotype in bENaC-overexpressing mice (Figure 1, and Figures
E3A–E3D).
Figure 1. Preventive amiloride therapy reduces mortality, airway mucus obstruction, and epithelial remodeling in b-subunit of the epithelial Na1
channel (bENaC)-overexpressing mice. Effect of preventive amiloride treatment, administered from the first day of life for a period of 2 weeks on (A)
survival; (B and C) airway mucus content, (D) goblet cell counts, and (E) epithelial height in bENaC-overexpressing (bENaC-Tg) mice and wild-type
(WT) littermates. (A) Survival curves for bENaC-overexpressing and wild-type mice treated with amiloride or vehicle alone (n 5 46–86 mice for each
group; *P , 0.001 compared with vehicle-treated bENaC-overexpressing mice). (B) Airway histology of bENaC-overexpressing and wild-type mice
after preventive treatment with amiloride or vehicle. Sections were stained with Alcian blue–periodic acid Schiff (AB-PAS) to determine the presence
of intraluminal mucus and goblet cells. Representative of n 5 15–27 mice for each group. Scale bars 5 100 mm. (C) Mucus content was determined
by measuring the volume density of AB-PAS–positive material in proximal and distal main axial airways (n 5 15–27 mice for each group; *P , 0.001
compared with vehicle-treated wild-type, †P , 0.05 compared with vehicle-treated bENaC-overexpressing mice, ‡P , 0.001 compared with vehicle-
treated bENaC-overexpressing mice). (D) Goblet cell densities in proximal and distal main axial airways were determined from the number of AB-
PAS–positive epithelial cells per mm of the basement membrane (n 5 15–27 mice for each group; *P , 0.01 compared with vehicle-treated wild-
type, †P , 0.05 compared with vehicle-treated bENaC-overexpressing mice). (E) Epithelial height was determined by measuring the volume density
of the epithelium in main axial airways (n 5 15–27 mice for each group; *P , 0.001 compared with vehicle-treated wild-type, †P , 0.01 compared
with vehicle-treated bENaC-overexpressing mice).
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Amiloride Treatment Has No Effect on Mucus Obstruction,
Goblet Cell Metaplasia and Mortality in bENaC-overexpressing
Mice with Established CF-like Lung Disease
Based on the therapeutic benefits of preventive intranasal
amiloride therapy, we next mimicked the paradigm of previous
clinical trials in patients with CF (20, 21, 29) and tested the effect
of amiloride administration on mucus obstruction and mucus
hypersecretion in adult bENaC-overexpressing mice with estab-
lished CF-like lung disease. We started treatment at the age of
4 weeks, when bENaC-overexpressing mice exhibit chronic airway
mucus obstruction and remodeling with goblet cell metaplasia
and epithelial hypertrophy (15, 17), and continued treatment of
bENaC-overexpressing mice and their wild-type littermates by
intranasal instillation of amiloride or vehicle alone for a period of
Figure 2. Preventive amiloride
therapy reduces increased
mucin expression in bENaC-
overexpressing mice. (A–C) Ex-
pression levelsofMuc5ac,Gob5,
and bENaC transcripts in lungs
from wild-type and bENaC-
overexpressingmiceafter2 weeks
of preventive amiloride treat-
ment (n 5 13–15 mice for each
group; *P < 0.001 compared
with vehicle-treated wild-type,
†P , 0.05 compared with vehi-
cle-treated bENaC-overex-
pressing mice, ‡P , 0.01
compared with vehicle-treated
bENaC-overexpressing mice).
Figure 3. Late amiloride treatment in adult bENaC-overexpressing mice with chronic CF-like lung disease has no therapeutic effects on airway
mucus obstruction or goblet cell metaplasia. Effects of late amiloride treatment, administered from the age of 4 weeks for a period of 2 weeks on
(A and B) airway mucus content, (C) goblet cell counts, and (D) epithelial height in adult bENaC-overexpressing (bENaC-Tg) mice and wild-type
(WT) littermates (n 5 9–11 mice for each group). (A) Airway histology from adult bENaC-overexpressing mice and wild-type littermates
after administration of amiloride or vehicle for 2 weeks stained with AB-PAS to determine the presence of intraluminal mucus and goblet cells. Scale
bars 5 100 mm. (B) Mucus content was determined by measuring the volume density of AB-PAS–positive material in proximal and distal main axial
airways (*P , 0.01 compared with vehicle-treated wild-type). (C) Goblet cell densities in proximal and distal main axial airways were determined
from the number of AB-PAS–positive epithelial cells per mm of the basement membrane (*P , 0.001 compared with vehicle-treated wild-type). (D)
Epithelial height, as determined from measurement of epithelial volume density in main axial airways.
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2 weeks as for the preventive amiloride study (Figure 1). In
contrast to preventive therapy, initiating amiloride treatment in
adult mice reduced neither proximal nor distal airways mucus
obstruction (Figures 3A and 3B), nor goblet cell metaplasia
(Figure 3C) and epithelial thickening (Figure 3D) in amiloride-
treated versus vehicle-treated bENaC-overexpressing mice.
Because recent studies demonstrated that mucus plugging in
bENaC-overexpressing mice originates in the trachea during the
first week of life in the absence of goblet cell metaplasia and
intrapulmonary mucus obstruction (17), we asked if amiloride
therapy was still effective when treatment was started at the age of
5 days—that is, after the onset of proximal mucus plug formation,
but before the establishment of chronic lung disease in bENaC-
overexpressing mice. In contrast to preventive therapy adminis-
tered from the first day of life (Figure 1), initiating amiloride
treatment in mice that were alive at the age of 5 days for a period
of 2 weeks failed to reduce mortality in amiloride-treated versus
vehicle-treated bENaC-overexpressing mice (Figure 4A). Fur-
ther, initiating amiloride treatment at the age of 5 days had no
effect on airway mucus obstruction (Figure 4B), goblet cell
metaplasia (Figure 4C), or epithelial thickening (Figure 4D) in
bENaC-overexpressing mice. Collectively, these data demon-
strate that preventive amiloride treatment is effective in reducing
airway mucus obstruction, airway remodeling, mucin hyperse-
cretion, and pulmonary mortality (Figures 1 and 2), but that these
therapeutic effects were abrogated when treatment was started
after the onset of CF-like lung disease (Figures 3 and 4) in
bENaC-overexpressing mice.
Preventive Amiloride Therapy Reduces Airway Inflammation
in bENaC-overexpressing Mice
In addition to airway mucus obstruction and mucus hypersecre-
tion, chronic airway inflammation is an invariable feature of CF
lung disease, leading to progressive damage and remodeling of
the lung (30–32). We, therefore, next asked if preventive in-
tranasal amiloride therapy had therapeutic effects on airway
inflammation in bENaC-overexpressing mice. Consistent with
a Th2-biased immune system in the neonatal period (33, 34), we
have previously shown that spontaneous airway inflammation in
2-week-old bENaC-overexpressing mice is predominated by
eosinophils associated with morphologically activated macro-
phages (i.e., foam cells), elevated numbers of neutrophils, and
increased levels of the Th2-signaling molecule IL-13 (17). Eval-
uation of BAL fluid for inflammatory cells at the end of the
Figure 4. Initiating amiloride treatment in juvenile bENaC-overexpressing mice with established mucus plugging has no therapeutic effects on
airway mucus obstruction, goblet cell metaplasia, or pulmonary mortality. Effect of amiloride treatment, administered from the age of 5 days for
a period of 2 weeks on (A) survival, (B) airway mucus content, (C) goblet cell counts, and (D) epithelial height in juvenile bENaC-overexpressing
(bENaC-Tg) mice and wild-type (WT) littermates. (A) Survival curves for bENaC-overexpressing and wild-type mice treated with amiloride or vehicle
alone from the age of 5 days (n 5 18–34 mice for each group). (B) Mucus content in proximal and distal main axial airways (n 5 7–11 mice for each
group; *P , 0.001 compared with vehicle-treated wild-type). (C) Goblet cell counts in proximal and distal main axial airways (n 5 7–11 mice for
each group; *P , 0.01 compared with vehicle-treated wild-type). (D) Epithelial volume density as a measure of epithelial height was determined in
main axial airways (n 5 7–11 mice for each group; *P , 0.001 compared with vehicle-treated wild-type).
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2-week treatment period revealed that total cells and eosinophil
numbers were significantly reduced in amiloride-treated versus
vehicle-treated bENaC-overexpressing mice (Figures 5A and
5B). Notably, total macrophage numbers were not changed, but
macrophage activation was significantly reduced by preventive
amiloride therapy in bENaC-overexpressing mice (Figures 5A–
5C). The reduction of airway eosinophilia was paralleled by
a significant reduction in IL-13 levels in BAL from amiloride-
treated versus vehicle-treated bENaC-overexpressing mice (Fig-
ure 5D). In wild-type littermates, preventive amiloride therapy
did not have adverse effects on BAL cellularity, macrophage
morphology, or IL-13 concentration (Figures 5A–5D).
Incontrast to intranasal treatment, subcutaneous administration
of amiloride had no effect onBALinflammatory cell counts in bENaC-
overexpressing mice (Figure E3E). Taken together, our results show
that preventive topical inhibition of airway Na1 hyperabsorption
was efficient in reducing the chronic airway inflammation char-
acteristic of the CF-like lung disease in bENaC-overexpressing mice.
Amiloride Treatment Has No Effect on Airway Inflammation
in bENaC-overexpressing Mice with Established CF-like
Lung Disease
Next, we evaluated the effects of amiloride intervention on airway
inflammation in 5-day-old (Figures 6A, 6C, and 6E) and 4-week-
old (Figures 6B, 6D, and 6F) bENaC-overexpressing mice with
established CF-like lung disease (15, 17). In contrast to the
antiinflammatory effects provided by preventive amiloride ther-
apy, starting amiloride treatment after the onset of lung disease
had no effect on elevated BAL inflammatory cell counts (Figures
6A and 6B), morphologic macrophage activation (Figures 6C and
6D), or IL-13 levels in BAL (Figures 6E and 6F) from amiloride-
treated versus vehicle-treated bENaC-overexpressing mice.
Therapeutic Effects of Preventive Amiloride Treatment Were
Not Sustained if Treatment Was Discontinued in
bENaC-overexpressing Mice
Next, we performed amiloride withdrawal studies to determine if
therapeutic effects of preventive amiloride treatment (Figures 1
and 5) were sustained, or if airway mucus obstruction and airway
inflammation recurred, when amiloride treatment was stopped in
bENaC-overexpressing mice. In these studies, amiloride or
vehicle alone were applied from the first day of life for a period
of 2 weeks as described for the experiments shown in Figures 1
and 5. Then treatment was discontinued, mice were monitored for
survival, and BAL was performed and lungs of mice from all
treatment groups were evaluated for mucus obstruction at the age
of 6 weeks. Withdrawal of amiloride treatment did not cause
recurrence of mortality in bENaC-overexpressing mice (data not
shown). However, the severity of airway mucus obstruction,
goblet cell metaplasia, epithelial hypertrophy, and BAL inflam-
matory cell counts were not different in bENaC-overexpressing
mice that were temporarily treated with either amiloride or
vehicle alone (Figure 7). These results demonstrate that early
but temporary amiloride therapy reduced neonatal mortality, but
did not have sustained therapeutic effects on mucus obstruction
and airway inflammation in bENaC-overexpressing mice.
Preventive Amiloride Therapy Reduces Epithelial Necrosis in
bENaC-overexpressing Mice
The mechanistic links between increased epithelial Na1 absorp-
tion, reduced ASL volume, and airway inflammation in the
bENaC-overexpressing mouse are likely multiple. One clue to
such a link emanates from recent studies that demonstrated that
neonatal (but not 4-wk-old) bENaC-overexpressing mice de-
velop airway epithelial hypoxia and epithelial cell necrosis, likely
Figure 5. Preventive amiloride therapy reduces airway inflammation in bENaC-overexpressing mice. Effect of preventive treatment with amiloride
or vehicle alone, administered from the first day of life for a period of 2 weeks, on (A) macrophage morphology, (B) inflammatory cell counts, (C)
macrophage size, and (D) concentration of the Th2 cytokine IL-13 in bronchoalveolar lavage (BAL) from bENaC-overexpressing (bENaC-Tg) mice
and wild-type (WT) littermates. (A) Morphology of BAL macrophages (stained with May Grünwald Giemsa). Representative of n 5 24–40 mice for
each group. Scale bars 5 20 mm. (B) BAL cell counts (n 5 24–40 mice for each group; *P , 0.05 compared with vehicle-treated wild-type, **P ,
0.001 compared with vehicle-treated wild-type, †P , 0.05 compared with vehicle-treated bENaC-overexpressing mice, ‡P , 0.001 compared with
vehicle-treated bENaC-overexpressing mice). (C) Size of BAL macrophages as a marker for macrophage activation (n 5 14–30 mice for each group;
*P , 0.001 compared with vehicle-treated wild-type, †P , 0.01 compared with vehicle-treated bENaC-overexpressing mice). (D) IL-13
concentration in BAL (n 5 7–28 mice for each group; *P , 0.01 compared with vehicle-treated wild-type, †P , 0.01 compared with vehicle-
treated bENaC-overexpressing mice).
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resulting from combined effects of increased epithelial O2 con-
sumption due to Na1 hyperabsorption and decreased O2 delivery
due to airway mucus plugging (17). Because necrotic debris is
a consistent finding in the small airways of patients with CF (35),
and cellular necrosis is a potent trigger for inflammation (36), we
evaluated the effects of preventive amiloride treatment starting
on the first day of life on the occurrence of necrotic epithelial cells
in airways of 3-day-old bENaC-overexpressing neonates (Figure
8). Notably, compared with vehicle treatment, preventive admin-
istration of amiloride significantly reduced the frequency of
necrotic airway epithelial cells in neonatal bENaC-overexpress-
ing mice (Figures 8A and 8B), demonstrating that preventive
ENaC blocker therapy protected epithelial cells from necrosis
and, thus, reduced a strong stimulus for airway inflammation.
DISCUSSION
In the present study, we used the bENaC-overexpressing mouse
as a model of CF lung disease (15, 16) to test the timing of
strategies that inhibit increased ENaC-mediated airway Na1
absorption to treat CF lung disease in vivo. Our results show for
the first time that preventive inhibition of accelerated Na1
absorption by the ENaC blocker amiloride is an effective therapy
for CF-like lung disease in a murine disease model. Preventive
amiloride administration exhibited significant therapeutic bene-
fits by reducing airway mucus obstruction, goblet cell metaplasia,
mucus hypersecretion, airway epithelial necrosis, and pulmonary
inflammation in bENaC-overexpressing mice (Figures 1, 2, 5, and
8). These therapeutic benefits resulted in an approximately 70%
reduction in spontaneous pulmonary mortality, and provide
a proof of concept for a novel therapeutic strategy for CF lung
disease (Figures 1, 2, 5, and 8). In contrast to currently available
CF therapies that target secondary pathogenetic events (i.e.,
antiinfective compounds for the treatment of bacterial infections
[32, 37] and inhaled DNase to antagonize increases in sputum
viscoelasticity caused by high levels of DNA released from in-
flammatory cells [38, 39]), preventive inhibition of increased Na1
absorption constitutes a pharmacologic strategy that targets a prox-
imal mechanism involved in the pathogenesis of CF lung disease.
We used the bENaC-overexpressing mouse for these studies
because previous work demonstrated that CF mice, either de-
ficient of CFTR or carrying specific CFTR mutations, do not
mimic increased Na1 absorption in the lower airways and do not
develop spontaneous airway mucus plugging, goblet cell meta-
plasia, and airway inflammation characteristic of CF lung disease
in humans (8, 10, 40, 41). Therefore, CF mice were not directly
useful for preclinical evaluation of ENaC directed therapies in CF
lung disease. However, besides dysregulation of cAMP-depen-
dent Cl2 secretion and ENaC-mediated Na1 absorption, CFTR
deficiency and/or malfunction has been implicated in various
other cellular dysfunctions, including abnormal receptor-medi-
ated clearance of bacteria, phagosome acidification in macro-
phages, cellular lipid trafficking, and ceramide metabolism (42–
46). Because CFTR function is normal in bENaC-overexpressing
mice, efficient therapy of CF lung disease may be more complex in
humans, and may require correction of other cellular dysfunc-
tions in addition to increased airway Na1 absorption. The
development of compounds that correct and/or potentiate dys-
functional CFTR (47–49) will help elucidate the relative impor-
tance of increased airway Na1 absorption versus defects in other
CFTR-mediated functions as targets for CF pharmacotherapy.
Interestingly, in addition to mucolytic effects, preventive
amiloride therapy had potent effects on airway inflammation in
bENaC-overexpressing mice (Figure 5). We speculate that the
antiinflammatory effects of amiloride may be mediated by several
mechanisms. First, we previously hypothesized that chronic
Figure 6. Late amiloride therapy has no effect on airway inflammation in bENaC-overexpressing mice. (A–E) Effect of late amiloride treatment,
administered from the age of (A, C, and E) 5 days or (B, D, and F) 4 weeks for a period of 2 weeks, on (A and B) cell counts, (C and D) macrophage
size, and (E and F) IL-13 concentrations in BAL from bENaC-overexpressing and wild-type mice. (A and B) BAL cell counts after treatment with
amiloride or vehicle alone from the age of (A) 5 days or (B) 4 weeks (n 5 13–34 mice for each group; *P , 0.01 compared with vehicle-treated wild-
type, **P , 0.001 compared with vehicle-treated wild-type). (C and D) Size of BAL macrophages after treatment from (C) 5 days or (D) 4 weeks (n 5
7–11 mice for each group; *P , 0.05 compared with vehicle-treated wild-type). (E and F) IL-13 concentration in BAL after treatment from (E) 5 days
or (F) 4 weeks (n 5 4–17 mice for each group; *P , 0.01 compared with vehicle-treated wild-type).
Zhou, Treis, Schubert, et al.: Preventive Amiloride Therapy for CF Lung Disease 1251
 
airway inflammation may be triggered by a failure to clear inhaled
particulates and irritants, which induce expression of proinflam-
matory cytokines like keratinocyte chemoattractant (KC) by macro-
phages and/or airway epithelia in bENaC-overexpressing mice
(15, 50). We therefore predict that antiinflammatory effects may
be conferred by improved clearance of proinflammatory stimuli
when airway Na1 hyperabsorption and ASL depletion were
prevented by amiloride. Second, we recently demonstrated that
neonatal bENaC-overexpressing mice develop airway epithelial
necrosis, likely reflecting increased epithelial O2 consumption
due to ENaC-mediated Na1 hyperabsorption and/or decreased
O2 delivery due to airway mucus plugging (17). Because necrosis
is a strong trigger for inflammation (36), we predict that inhibition
of this phenotype by preventive amiloride shown in this study
(Figure 8) also reduced a potent stimulus for airway inflammation
in bENaC-overexpressing mice. Third, amiloride has been shown
to inhibit secretion of proinflammatory cytokines including IL-8
and TNF-a in alveolar macrophages, and that this antiinflamma-
tory action is mediated by inhibition of the Na1/H1 exchanger
(NHE) (51), rather than by ENaC blockade. Future studies with
more selective blockers (51, 52) are required to determine the
relative roles of ENaC versus NHE as targets for antiinflamma-
tory therapy of CF-like lung disease in bENaC-overexpressing
mice.
Our observation that amiloride therapy became ineffective
when treatment was started after the onset of CF-like lung disease
in bENaC-overexpressing mice (Figures 3, 4, and 6) is consistent
with previous clinical trials in patients with established CF
lung disease (20, 21). The failure of amiloride inhalation therapy
in patients with CF was mainly attributed to: (1) insufficient
pulmonary delivery of amiloride due to limited solubility restrict-
ing the amount that could be delivered by a nebulizer; (2) limited
potency; and (3) limited half-life of amiloride on airway surfaces
(53–55). Our findings showing that amiloride can be delivered to
the lung in therapeutically active quantities before the onset of
lung disease suggest that airway mucus obstruction and/or airway
remodeling were contributing factors to the absence of therapeu-
tic benefits in older bENaC-overexpressing mice and patients
with CF with established lung disease.
In this context, previous studies demonstrated that single viral
infections of the respiratory tract not only cause acute bronchio-
litis, but can also trigger chronic responses with goblet cell
metaplasia and mucus hypersecretion that persist for many years
after viral clearance (56). Emerging evidence suggests that
persisting airway disease may be caused by viral reprogramming
of the epithelium and/or components of the innate and adaptive
immune system in a susceptible host, and that this mechanism
may be implicated in the pathogenesis of chronic airway diseases
Figure 7. Therapeutic effects of preventive amiloride treatment are not sustained if treatment is withdrawn in bENaC-overexpressing mice.
Summary of amiloride withdrawal studies. bENaC-overexpressing (bENaC-Tg) mice and wild-type (WT) littermates were treated with amiloride
from birth for a period of 2 wk, then treatment was withdrawn and effects on (A) airway mucus content, (B) goblet cell counts, (C) epithelial height,
and (D) inflammatory cell counts were evaluated in 6-week-old adult mice (n 5 6–10 mice for each group). (A) Mucus content in proximal and distal
main axial airways (*P < 0.001 compared with vehicle-treated wild-type). (B) Goblet cell counts in proximal and distal main axial airways (*P , 0.05
compared with vehicle-treated wild-type). (C) Epithelial height was determined by measuring epithelial volume density in main axial airways (*P ,
0.05 compared with vehicle-treated wild-type). (D) Total and differential BAL cell counts (*P , 0.05 compared with vehicle-treated wild-type, **P <
0.001 compared with vehicle-treated wild-type).
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such as asthma and chronic bronchitis (56, 57). We speculate that
early mucus obstruction and inflammation caused by ASL de-
pletion in CF lung disease may provide an alternative stimulus
that reprograms host cell behavior to produce chronic airway
disease. While future studies are required to elucidate the
mechanisms that impede therapeutic effects of amiloride in
bENaC-overexpressing mice and patients with CF with estab-
lished airway disease, our results point to the possibility that
a preventive ENaC blocker treatment paradigm may be required
for effective therapy of CF lung disease.
The concept that a single viral infection in a vulnerable period
could trigger prolonged airways disease (56) led us to speculate
that the lung disease in adult bENaC-overexpressing mice may
reflect a sustained change in airway cell populations and/or
function that resulted from early (3–10 d) pathologic events
(17). We, therefore, tested the hypothesis that early inhibition
of airway epithelial dysfunction by preventive ENaC blocker
therapy may have durable effects by performing amiloride with-
drawal protocols, in which preventive amiloride therapy was
discontinued in juvenile mice and lungs were evaluatedafter a 4-week
off treatment period. These studies demonstrated that stopping
amiloride therapy resulted in recurrence of airway mucus obstruc-
tion, epithelial remodeling, and airway inflammation in adult
bENaC-overexpressing mice (Figure 7) (17). However, with-
drawal of amiloride treatment in surviving juvenile bENaC-
overexpressing mice did not cause recurrence of mortality. Our
previous studies demonstrated that death in neonatal bENaC-
overexpressing mice is caused by severe mucus plugging of the
trachea (17). We speculate that the growth-related increase in
cross-sectional surface area of the trachea protected juvenile
bENaC-overexpressing mice from life-threatening airflow limita-
tion after amiloride therapy was discontinued and mucus accumu-
lation recurred. Taken together, the observation that temporary
inhibition of increased airway Na1 absorption prevented early
mortality, but did not have lasting therapeutic effects on airway
mucus obstruction and inflammation in bENaC-overexpressing
mice, suggests that continuous ENaC blocker therapy may be
required to optimize long-term treatment benefits in CF lung disease.
Regarding the feasibility of preventive amiloride therapy in
patients with CF, only limited information is available on the
timing of the onset and early progression of CF lung disease in
humans. Pathologic studies demonstrated that lungs were struc-
turally normal in CF neonates who died of intestinal obstruc-
tion, but that airway mucus plugging associated with air
trapping and atelectasis developed in the first months of life
(58, 59). These findings suggest that inhaled amiloride therapy is
unlikely to be beneficial for patients with CF who are diagnosed
in infancy or early childhood on the basis of clinical symptoms.
On the other hand, these pathologic studies indicate that in the
first weeks and months of life, there is a window for preventive
therapy in the human CF lung. Importantly, recent develop-
ments in CF neonatal screening allow establishing a CF di-
agnosis in this critical life span (60, 61). We, therefore, predict
that near-birth initiation of preventive amiloride therapy may
become feasible in a larger number of patients with CF in the
near future.
Previous pharmacokinetic studies in healthy subjects demon-
strated that targeting the lung with aerosols produced therapeutic
amiloride concentrations on airway surfaces in a structurally
normal lung (53, 62). Importantly, previous clinical studies
documented that long-term inhalation of aerosolized amiloride
at concentrations of 1 to 10 mmol/L (equivalent to doses of 0.1 to 1
mg/kg body weight per day), was well tolerated, safe, and did not
cause diuresis or electrolyte imbalance in humans (20, 21, 29). In
mice, intranasal instillation is commonly used for pulmonary
delivery of drugs or allergens (63). Pulmonary delivery is likely
mediated by generation of an aerosol within the nose, which is
deposited onto the lower airways. Our deposition studies in-
dicated that intranasal instillation in mice produced a pulmonary
deposition fraction (z 4%) that was substantially smaller than
that achieved by aerosol inhalation in humans (Figure E1) (20, 21,
29, 53, 64, 65). Further, initial dose–response studies indicated
that high doses of intranasal amiloride (z 8 mg/kg body weight
per day) were required to reduce pulmonary mortality in neo-
natal bENaC-overexpressing mice (Figure E2). These results
indicate that the high intranasal amiloride dose administered in
our study was required to compensate for inefficient intrapulmo-
nary deposition. The diuretic effects caused by intranasal ami-
loride instillation in mice (Figure E1) indicated that much of the
intranasally deposited amiloride was swallowed and absorbed
from the gastrointestinal tract, causing systemic effects by in-
hibition of ENaC in the kidney.
Figure 8. Preventive amiloride therapy reduces airway epithelial necrosis in bENaC-overexpressing mice. Effect of preventive amiloride treatment,
administered from the first day of life for a period of 3 days, on (A) airway histology and (B) numbers of degenerative airway epithelial cells in bENaC-
overexpressing (bENaC-Tg) mice and wild-type (WT) littermates. (A) Airway histology of 3-day-old bENaC-overexpressing and wild-type mice after
preventive treatment with amiloride or vehicle alone. Sections were stained with hematoxylin and eosin to determine the numbers of degenerative
airway epithelial cells (arrows). Representative of n 5 7–12 mice for each group. Scale bars 5 20 mm (upper panels) or 10 mm (lower panels). (B)
Severity of airway epithelial necrosis was determined from the number of degenerative epithelial cells per mm of the basement membrane (n 5 7–
12 mice for each group; *P < 0.001 compared with vehicle-treated wild-type, †P , 0.001 compared with vehicle-treated bENaC-overexpressing
mice).
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Gastrointestinal absorption, therefore, can account for the
diuretic effects, but also raised the possibility that therapeutic
effects of intranasal amiloride therapy in bENaC-overexpressing
mice (Figures 1 and 2) were mediated by systemic, rather than
topical, ENaC inhibition in airway epithelia. To address this
possibility, we treated mice systemically by subcutaneous ami-
loride injections with doses equivalent to the doses used for
intranasal therapy (Figure E3). In these studies, preventive
systemic amiloride treatment caused more severe weight loss,
likely due to profound diuresis, but did not have therapeutic
effects on the lung disease in bENaC-overexpressing mice. Taken
together, these findings support the concept that therapeutic
benefits of preventive intranasal amiloride in bENaC-overex-
pressing mice were conferred by topical blockade of ENaC in the
airways, and predict that substantially lower doses will be re-
quired to deliver amiloride in pharmacologically active concen-
trations to the lungs of CF infants with efficient aerosol delivery
systems (64, 65).
The low potency of amiloride and its short half-life on airway
surfaces limited the ability of our studies, as well as previous
clinical trials (20, 21), to address whether ENaC-directed thera-
pies can be beneficial in established CF lung disease (53–55).
These limitations have led to the development of a series of novel
more potent and durable amiloride analogs designed specifically
for inhalation therapy of CF lung disease (52, 66). Recent in vitro
studies demonstrated that the selected compound 552-02 was 60-
to 100-fold more potent, up to fivefold less reversible, and twofold
more slowly absorbed from surfaces of airway epithelia than
amiloride (52). Compared with amiloride, compound 552-02
produced greater ASL expansion in airway cultures in vitro and
was more effective at increasing mucus clearance in sheep. These
results indicate that highly potent and long-acting ENaC blockers
may be more effective than amiloride, both in the prevention and
therapy of CF lung disease. We predict that future studies in
bENaC-overexpressing mice will help to evaluate the efficacy
and safety of these compounds, including their therapeutic effects
in established lung disease, at the preclinical level.
As novel chemical entities, compounds such as 552-02 will first
have to undergo preclinical evaluation and toxicity testing and
are, therefore, years away from routine clinical use, especially for
preventive therapy in very young patients with CF. In contrast,
amiloride is inexpensive, readily available, and has been in
clinical use as a diuretic for many years. We predict that these
properties, together with a widespread implementation of CF
newborn screening programs (60, 61), and recent improvements
in nebulizer technology allowing enhanced aerosol delivery to the
neonatal and infant human lung (64, 65), may facilitate the
translation of preventive amiloride therapy for CF lung disease
from mice to the clinic.
We hypothesized that the predominant eosinophilic airway
inflammation observed in juvenile (2- to 3-wk-old) bENaC-
overexpressing mice was triggered by impaired clearance of
inhaled airborne allergens in a Th2-biased host (17, 33, 34). Here,
we demonstrate that characteristic features of this allergic airway
inflammation, including airway eosinophilia and elevated IL-13,
were effectively reduced by preventive amiloride therapy. Fur-
thermore, recent evidence indicated that exposure to cigarette
smoke decreases CFTR expression and cAMP-dependent Cl2
secretion in airway epithelia in vivo, suggesting that ASL de-
pletion may also be implicated in the pathogenesis of reduced
airway mucus clearance observed in smokers and patients with
chronic bronchitis (67–69). In summary, our results suggest that
improving ASL hydration by preventive inhalation therapy with
the ENaC blocker amiloride may be of benefit for the treatment
of CF, and potentially other chronic lung diseases associated with
mucociliary dysfunction, including chronic bronchitis and asthma.
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